• 1
    Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463472.
  • 2
    Tong MJ, Lee SY, Hywang SJ, Co RL, Lai PP, Chien D, Kuo G. Evidence for hepatitis C viral infection in patients with primary hepatocellular carcinoma. West J Med 1994; 160: 133138.
  • 3
    Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995; 15: 514.
  • 4
    Belle SH, Beringer KC, Detre KM. An update on liver transplantation in the United States: recipient characteristics and outcome. In: TerasakiPI, CeckaJM, eds. Clinical Transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1995: 1933.
  • 5
    Hoofnagle JH, Mullen KD, Jones DB, Rustigi V, DiBisceglie A, Peters M, Waggoner JG, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alfa interferon. A preliminary report. N Engl J Med 1986; 315: 15751578.
  • 6
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 15011506.
  • 7
    Marcellin P, Boyer N, Giostra E, Degott C, Courcouce AM, Degos F, Coppere H, Cales P, et al. Recombinant human (alpha) interferon in patients with chronic non-A and non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393397.
  • 8
    Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud J-P, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991; 101: 497502.
  • 9
    Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347356.
  • 10
    Davis GL, Lindsay K, Albrecht J, Bodenheimer HC, Balart LA, Perrillo RP, Dienstag JL, et al. Clinical predictors of response to recombinant interferon alpha treatment in patients with chronic non-A non-B hepatitis (hepatitis C). J Viral Hepatitis 1994; 1: 5563.
  • 11
    Serfaty L, Giral P, Loria A, Andreani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994; 21: 1217.
  • 12
    Martinot-Peignoux M, Narcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 221: 10501056.
  • 13
    Yamada G, Takatani M, Kishi F, Takahashi M, Toshihiko D, Tsuji T, Shin S, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995; 22: 13511354.
  • 14
    Stuyver L, Rossau R, Wyscur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1903; 74: 10931102.
  • 15
    Simmonds P, Albert P, Alter J II, Bonino F, Bradley DW, Brechot C, Brouwer JT, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 13211324.
  • 16
    Tong MJ, Hwang SJ, Lefkowitch M, Lee SD, Co RL, Conrad A, Schmid Lo KJ. Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin. J Gastroenterol Hepatol 1994; 9: 587591.
  • 17
    Friis RH, Stellers TA. Epidemiology for public health practice. Gaithers-burg, MD: Aspen, 1996.
  • 18
    Lau JYN, Mizokami M, Ohno T, Diamond DA, Kniffen J, Davis GL. Discrepancy between biochemical and virological responses to interferon alpha in chronic hepatitis C. Lancet 1993; 342: 12081209.
  • 19
    Chemello L, Cavalletto L, Casarin C, Bonetti P, Bernardinello E, Pontisso P, Donada C, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon alpha in chronic hepatitis C. Ann Intern Med 1996; 124: 10581060.
  • 20
    Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778789.
  • 21
    Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26: 122S127S.
  • 22
    McHutchison JG, Blatt LM, Russell J, Conrad A. Kinetics of changes in serum HCV RNA during interferon therapy in patients with chronic HCV infection [Abstract]. Gastroenterology 1997; 112: A1330.
  • 23
    Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon alpha and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995; 21: 100310.
  • 24
    Castilla A, Prieto J, Fausto N. Transforming growth factors bl and alpha in chronic liver disease. N Engl J Med 1991; 324: 99340.
  • 25
    Ziol M, Van Nhieu JT, Roudot-Thorovol F, Metreau JM, Deugnier Y, Dhumeaux D, Zafrani ES. A histopathological study of the effects of 6-month versus 12-month interferon alpha 2b therapy in chronic hepatitis C. J Hepatol 1906; 25: 833841.
  • 26
    Jensen D, Shafritz D, Craig JR, Krawitt E. Nonresponders to CIFN show clinically relevant improvements in liver histology [Abstract]. Gastroenterology 1997; 112: A1294.
  • 27
    Knodell RG, Kmal IG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431435.